Dopamine transporter loss and clinical changes in MPTP-lesioned primates

Jamie L. Eberling, Krzysztof S. Bankiewicz, Phillip Pivirotto, John Bringas, Karen Chen, David P. Nowotnik, Joseph P. Steiner, Thomas F. Budinger, William J. Jagust

Research output: Contribution to journalArticlepeer-review

Abstract

Single photon emission computed tomography (SPECT) and the dopamine (DA) transporter tracer, 2 beta-carboxymethoxy-3 beta-(4-iodophenyl)tropane ([123I][β-CIT), were used to determine DA transporter density in 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with varying degrees of parkinsonism. The clinical stage of parkinsonism corresponded to SPECT measures of striatal DA transporter density suggesting that more severe parkinsonism was associated with a greater degree of dopaminergic terminal degeneration. These findings are similar to those reported earlier using positron emission tomography (PET) and the DA metabolism tracer, 6-[18F]fluoro-L-m-tyrosine (FMT), indicating that both are good methods for evaluating nigrostriatal degeneration in MPTP primate models.

Original languageEnglish (US)
Pages (from-to)184-187
Number of pages4
JournalBrain research
Volume832
Issue number1-2
DOIs
StatePublished - Jun 19 1999

Keywords

  • Dopamine transporter
  • MPTP
  • Monkey
  • Parkinson's disease
  • Single photon emission computed tomography
  • β-CIT

ASJC Scopus subject areas

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology

Fingerprint

Dive into the research topics of 'Dopamine transporter loss and clinical changes in MPTP-lesioned primates'. Together they form a unique fingerprint.

Cite this